Literature DB >> 4030462

Acute hemodynamic effects of hydralazine in dogs with chronic mitral regurgitation.

M D Kittleson, L E Johnson, N B Oliver.   

Abstract

The hemodynamic response to hydralazine administration was evaluated in 6 conscious small dogs with chronic mitral regurgitation. All dogs underwent invasive and noninvasive hemodynamic monitoring before and after hydralazine administration. Cardiac output and pulmonary capillary wedge pressure were measured with a Swan-Ganz thermodilution catheter. Systemic arterial blood pressure (AP) was measured directly by inserting a needle into the femoral artery. Standard M-mode echocardiograms and thoracic radiographs were obtained. Other hemodynamic variables were calculated. Base-line hemodynamic variables were altered severely in all dogs. Hydralazine decreased mean arterial blood pressure from 104 +/- 18 (mean +/- SD) to 78 +/- 12 mm of Hg (P less than 0.005), total systemic resistance index from 2,946 +/- 625 to 1,261 +/- 420 dynes-s-cm-5m2 (P less than 0.005), and pulmonary capillary wedge pressure from 40 +/- 5 to 26 +/- 3 mm of Hg, (P less than 0.005). Cardiac index increased from 2.92 +/- 0.72 to 5.36 +/- 1.67 L/min/m2 of body surface area (P less than 0.005). Mixed venous oxygen tension (PvO2) increased from 28.4 +/- 4.3 to 41.2 +/- 5.2 mm of Hg (P less than 0.001). Pulmonary edema resolved, as determined on thoracic radiographs. Mixed venous oxygen tension correlated well with the cardiac index (r = 0.92; P less than 0.001). It was concluded that hydralazine administration caused a small decrease in end diastolic diameter (4.8 +/- 0.9 to 4.5 +/- 0.8 cm, P less than 0.05) and end systolic diameter (2.6 +/- 0.8 to 2.3 +/- 0.7 cm, P less than 0.05). Fractional shortening and heart rate did not change.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4030462

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  4 in total

1.  Survival and echocardiographic data in dogs with congestive heart failure caused by mitral valve disease and treated by multiple drugs: a retrospective study of 21 cases.

Authors:  Eric de Madron; Jonathan N King; Günther Strehlau; Regina Valle White
Journal:  Can Vet J       Date:  2011-11       Impact factor: 1.008

2.  Hydralazine pharmacokinetics and interaction with food: an evaluation of the dog as an animal model.

Authors:  H A Semple; Y K Tam; R T Coutts
Journal:  Pharm Res       Date:  1990-03       Impact factor: 4.200

3.  Current concepts in vasodilator therapy for advanced or refractory congestive heart failure.

Authors:  M S Miller; M R O'grady; F W Smith
Journal:  Can Vet J       Date:  1988-04       Impact factor: 1.008

Review 4.  Management of Chronic Congestive Heart Failure Caused by Myxomatous Mitral Valve Disease in Dogs: A Narrative Review from 1970 to 2020.

Authors:  Mara Bagardi; Viola Zamboni; Chiara Locatelli; Alberto Galizzi; Sara Ghilardi; Paola G Brambilla
Journal:  Animals (Basel)       Date:  2022-01-16       Impact factor: 2.752

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.